内部人交易雷达

美国 · SEC Form 4 · 快照日期： 2026-10-18 · 构建时间： 2026-10-18 · English

← 美国市场 · 覆盖记录

美国 · SEC FORM 4

REGENXBIO Inc.

RGNX · Nasdaq · CIK 0001590877 · Healthcare · Biotechnology

内部人信号

37.9 / 100

1 位买方 · 2 条买入交易行 · $949.5K 买入总额

为什么有这个信号？

买方广度较低
买入规模较低
角色较强
近期性较低
确信度较低
评分构成

每条进度条表示其对当前分数的贡献；权重和公式保持不变。

Cluster+7.0 / 35
买入规模+6.0 / 25
角色+20.0 / 20
近期性+4.2 / 10
确信度+0.7 / 10

哪些因素限制了当前分数？

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Buying conviction is reduced by concurrent selling
  • ✓ 角色得分高 · 买入者中职位最高的是：Director

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。

内部人活动时间轴

申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。

AprMayJunJulAugSepOct
PAKOLA STEVEChief Medical Officer
▼▼○▼○▼○
Ciongoli Gregory AustinDirector
○●●
Simpson CurranChief Executive Officer
○○
Malzahn CraigChief Technology Officer
○
Chan MitchellChief Financial Officer
○
Christmas Patrick J.Chief Strategy & Legal Officer
○
● 买入▼ 卖出○ 其他

Showing the six most active owners; 9 additional owner(s) remain in Form 4 申报证据.

买方广度与集中度

合资格买方1
买入集中度100%最大买方： Ciongoli Gregory Austin · $949.5K
聚集买入 · 15天1 insider峰值活动： 2026-08-26–2026-08-27

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

信号历史

37.9 / 100

最新留档分数

↓ -0.2 pts相对上一个留档快照
  1. 38.5
  2. 38.3
  3. 38.2
  4. 38.1
  5. 37.9

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

近期 Form 4 活动

2买入
5卖出
32其他 Form 4 交易行
31SEC 申报 · 365天
买入2 qualifying P line(s) · 180 days
卖出4 sale line(s) · 仅供背景
其他18 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

市场背景补充近期价格表现与风险信息，不影响内部人信号。

价格表现

1M
-5.7%
3M
-36.7%
6M
-8.3%
12M
-34.0%

波动率与流动性

波动率
89.3%
Beta
—
平均每日成交额
USD 11.9M

估值

市值
USD 532.7M
P/E
—

基本面

利润率
-113.8%
ROE
-188.7%
细分行业
Biotechnology

市场数据

价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, 利润率, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-07-31 · Status: PASS

空头余额

空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。

空头股数
9,608,992
上期报告
7,927,603
日均成交量
1,603,635
回补天数
6.0

FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting owner类型证券股数平均价格估算金额来源
2026-08-27Ciongoli Gregory Austin买入 (P)Common Stock53,407USD 9.36USD 499,890SEC 申报 ↗
2026-08-26Ciongoli Gregory Austin买入 (P)Common Stock49,196USD 9.14USD 449,651SEC 申报 ↗

Form 4 申报证据

39 transaction lines in the latest 365-day window; 312 in local history.

日期申报人类型证券股数平均价格估算金额来源
2026-09-01Malzahn Craig代扣税 (F)Common Stock234USD 9.32USD 2,181SEC 申报 ↗
2026-09-01Chan Mitchell代扣税 (F)Common Stock4,902USD 9.32USD 45,687SEC 申报 ↗
2026-08-27Ciongoli Gregory Austin买入 (P)Common Stock53,407USD 9.36USD 499,890SEC 申报 ↗
展开近期 Form 4 证据 (30 grouped rows)
日期申报人类型证券股数平均价格估算金额来源
2026-09-01Malzahn Craig代扣税 (F)Common Stock234USD 9.32USD 2,181SEC 申报 ↗
2026-09-01Chan Mitchell代扣税 (F)Common Stock4,902USD 9.32USD 45,687SEC 申报 ↗
2026-08-27Ciongoli Gregory Austin买入 (P)Common Stock53,407USD 9.36USD 499,890SEC 申报 ↗
2026-08-26Ciongoli Gregory Austin买入 (P)Common Stock49,196USD 9.14USD 449,651SEC 申报 ↗
2026-08-25Ciongoli Gregory Austin奖励／授予 (A)Common Stock15,432USD 0.00USD 0SEC 申报 ↗
2026-08-01PAKOLA STEVE代扣税 (F)Common Stock7,468USD 9.69USD 72,365SEC 申报 ↗
2026-08-01Christmas Patrick J.代扣税 (F)Common Stock4,699USD 9.69USD 45,533SEC 申报 ↗
2026-07-02PAKOLA STEVE卖出 (S)Common Stock2,161USD 13.64USD 29,476SEC 申报 ↗
2026-07-02PAKOLA STEVE期权行权／转换 (M)Common Stock2,161USD 7.86USD 16,985SEC 申报 ↗
2026-07-01Simpson Curran代扣税 (F)Common Stock6,818USD 13.09USD 89,248SEC 申报 ↗
2026-07-01PAKOLA STEVE卖出 (S)Common Stock36,725USD 12.86USD 472,284SEC 申报 ↗
2026-07-01PAKOLA STEVE期权行权／转换 (M)Common Stock36,725USD 7.86USD 288,658SEC 申报 ↗
2026-06-30Simpson Curran奖励／授予 (A)Common Stock1,453USD 10.18USD 14,792SEC 申报 ↗
2026-06-29PAKOLA STEVE卖出 (S)Common Stock19,608USD 11.04USD 216,472SEC 申报 ↗
2026-05-29Zachary Jennifer奖励／授予 (A)Common Stock9,807USD 0.00USD 0SEC 申报 ↗
2026-05-29Tasse Daniel奖励／授予 (A)Common Stock9,807USD 0.00USD 0SEC 申报 ↗
2026-05-29STUMP DAVID C奖励／授予 (A)Common Stock9,807USD 0.00USD 0SEC 申报 ↗
2026-05-29Mills Kenneth T.奖励／授予 (A)Common Stock9,807USD 0.00USD 0SEC 申报 ↗
2026-05-29MIGAUSKY GEORGE V奖励／授予 (A)Common Stock9,807USD 0.00USD 0SEC 申报 ↗
2026-05-29KARABELAS ARGERIS N奖励／授予 (A)Common Stock9,807USD 0.00USD 0SEC 申报 ↗
2026-05-29Glucksmann Alexandra奖励／授予 (A)Common Stock9,807USD 0.00USD 0SEC 申报 ↗
2026-05-29Fox Allan M.奖励／授予 (A)Common Stock9,807USD 0.00USD 0SEC 申报 ↗
2026-05-29Bennett Jean奖励／授予 (A)Common Stock9,807USD 0.00USD 0SEC 申报 ↗
2026-05-11PAKOLA STEVE卖出 (S)Common Stock15,309USD 11.02USD 168,705SEC 申报 ↗
2026-03-10PAKOLA STEVE卖出 (S)Common Stock5,124USD 10.35USD 53,033SEC 申报 ↗
2026-02-01PAKOLA STEVE代扣税 (F)Common Stock5,267USD 11.16USD 58,780SEC 申报 ↗
2026-02-01Christmas Patrick J.代扣税 (F)Common Stock4,700USD 11.16USD 52,452SEC 申报 ↗
2026-01-27Mills Kenneth T.期权行权／转换 (M)Common Stock225,000USD 13.09USD 2,945,250SEC 申报 ↗
2026-01-27Mills Kenneth T.代扣税 (F)Common Stock221,753USD 13.41USD 2,973,708SEC 申报 ↗
2026-01-06Simpson Curran奖励／授予 (A)Common Stock144,864USD 0.00USD 0SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期2026-10-18
排名版本US-v1.2
数据质量PASS ELIGIBLE · —
股票代码RGNX
CIK0001590877
行业Healthcare
细分行业Biotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
交易所Nasdaq

数据覆盖

本地 Form 4 历史312 transaction lines from 2020-01-08 to 2026-09-01
2 P purchase lines · 103 S sale lines · 207 other lines
SEC 公司申报打开 SEC 申报 ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.